Market access to orphan drugs

E-ISSN： 1440-1843|20|3|361-369

ISSN： 1323-7799

Source： RESPIROLOGY (ELECTRONIC), Vol.20, Iss.3, 2015-04, pp. : 361-369

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Orphan drugs: pricing, reimbursement and patient access

By Barak Adam Nandi Jyoti Shankar

International Journal of Pharmaceutical and Healthcare Marketing, Vol. 5, Iss. 4, 2011-11 ,pp. : 299-317

Emerald Group Publishing Ltd

Access to resources Recommend Favorite

The Challenges of Orphan Drugs and Orphan Diseases: Real and Imagined

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 92, Iss. 2, 2012-08 ,pp. : 151-153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rare Diseases and Orphan Drugs: A comprehensive approach of strategic perspectives

By Hansen Jan-C閐ric

Journal of Communication In Healthcare, Vol. 5, Iss. 4, 2012-12 ,pp. : 199-219

Maney Publishing

Access to resources Recommend Favorite

Do we need authorized orphan drugs when compounded medications are available?

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 38, Iss. 1, 2013-02 ,pp. : 1-2

John Wiley & Sons Inc

Access to resources Recommend Favorite

Do we need authorized orphan drugs when compounded medications are available?

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 269-4727, Iss. 1, 2013-02 ,pp. : 1-2

John Wiley & Sons Inc

Access to resources Recommend Favorite